Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. (Q33834742)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Adrian Streinu-Cercel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

M Colombo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

I Fernández

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

D Abdurakhmanov

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

P A Ferreira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S I Strasser

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C Moreno

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Verheyen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

W Iraqi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R DeMasi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Hill

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J M Läuffer

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

I Lonjon-Domanec

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

H Wedemeyer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

7 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1150-1158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting

29 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Antiviral strategies in hepatitis C virus infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Future treatment of patients with HCV cirrhosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Response-guided telaprevir combination treatment for hepatitis C virus infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Telaprevir for retreatment of HCV infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Telaprevir for previously untreated chronic hepatitis C virus infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Boceprevir for previously treated chronic HCV genotype 1 infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Boceprevir for untreated chronic HCV genotype 1 infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Diagnosis, management, and treatment of hepatitis C: an update

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4078754

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

4 July 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305667

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305667

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305667

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305667

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305667

10.1136/GUTJNL-2013-305667

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24201995%20AND%20SRC:MED&resulttype=core&format=json